summary
Introduced
11/20/2025
11/20/2025
In Committee
11/20/2025
11/20/2025
Crossed Over
Passed
Dead
Introduced Session
119th Congress
Bill Summary
A BILL To expand the drug price negotiation program under title XI of the Social Security Act and repeal certain changes to the program made by Public Law 119-21, to apply prescription drug inflation rebates under the Medicare program to drugs furnished in the commercial market, and to establish out-of-pocket limits on expenditures for prescription drugs under private health insurance.
AI Summary
This bill aims to lower drug costs for American families through several key provisions. First, it expands the drug price negotiation program under Medicare by increasing the number of drugs subject to price negotiations from 20 to 50, and allowing more health insurance plans to participate voluntarily in the program. The bill also requires consideration of international drug prices when negotiating, specifically looking at average prices in countries like Australia, Canada, France, Germany, Japan, and the United Kingdom. Additionally, the legislation establishes out-of-pocket limits on prescription drug expenses, capping annual drug costs at $2,000 for individuals and $4,000 for family coverage starting in 2027, with annual adjustments for inflation. The bill further includes a provision to limit insulin costs, requiring health plans to cap insulin products at $35 per 30-day supply or 25% of the negotiated price, without applying a deductible. The legislation also repeals certain previously enacted changes to the drug price negotiation program and applies prescription drug inflation rebates to drugs in the commercial market, potentially helping to reduce overall prescription drug costs for Americans.
Committee Categories
Business and Industry
Sponsors (50)
Frank Pallone (D)*,
Yassamin Ansari (D),
Joyce Beatty (D),
Suzanne Bonamici (D),
André Carson (D),
Judy Chu (D),
Yvette Clarke (D),
Jim Costa (D),
Joe Courtney (D),
Angie Craig (D),
Sharice Davids (D),
Suzan DelBene (D),
Chris Deluzio (D),
Maxine Dexter (D),
Debbie Dingell (D),
Lizzie Fletcher (D),
Lois Frankel (D),
Laura Friedman (D),
Robert Garcia (D),
Laura Gillen (D),
Dan Goldman (D),
Adelita Grijalva (D),
Steny Hoyer (D),
Julie Johnson (D),
Raja Krishnamoorthi (D),
Greg Landsman (D),
John Larson (D),
Ted Lieu (D),
John Mannion (D),
Doris Matsui (D),
April McClain-Delaney (D),
Jenn McClellan (D),
LaMonica McIver (D),
Richard Neal (D),
Eleanor Holmes Norton (D),
Ilhan Omar (D),
Mark Pocan (D),
Mike Quigley (D),
Emily Randall (D),
Josh Riley (D),
Jan Schakowsky (D),
Bobby Scott (D),
Lateefah Simon (D),
Melanie Stansbury (D),
Shri Thanedar (D),
Paul Tonko (D),
Lauren Underwood (D),
Eugene Vindman (D),
Debbie Wasserman Schultz (D),
Maxine Waters (D),
Last Action
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means, and Education and Workforce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (on 11/20/2025)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/119th-congress/house-bill/6166/all-info |
| BillText | https://www.congress.gov/119/bills/hr6166/BILLS-119hr6166ih.pdf |
Loading...